Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment
Status:
Recruiting
Trial end date:
2021-11-15
Target enrollment:
Participant gender:
Summary
The present study will be carried out to evaluate the antiallergic efficacy of Bepotastine
besilate 1.5% free of preservatives versus standard treatment with 0.2% Olopatadine
hydrochloride with 0.1% benzalkonium chloride as preservative in adult patients diagnosed
with allergic conjunctivitis.
The antiallergic efficacy will be evaluated by the reduction of ocular signs and symptoms and
by the resolution of non-ocular symptoms (rhinorrhea, congestion, and nasal pruritus), as
well as the effect of the preservative and its relationship with the cytotoxicity of the
ocular surface. Also will evaluate the safety of both products.